January 2024 Student Formulary – Preventive Care Medications with $0 Copay
Updates Effective 1/1/2024

U.S. Preventative Services Task Force A & B Recommendations

The Patient Protection and Affordable Care Act (PPACA) requires that certain health plans cover essential health benefits (EHB) without charging a copayment, coinsurance, or deductible. EHBs include a variety of preventative services and medications and are outlined by US Preventive Services Task Force (USPSTF) recommendations with an A or B rating. Based on the recommendations of USPSTF and the Centers for Disease Control and Prevention (CDC), Wellfleet Rx has identified preventative medications to be covered under the pharmacy benefit and updates this list of medications and coverage criteria as needed.

USPSTF and CDC recommendation updates can occur at any time, and health plans have specified timelines to implement these recommendations in compliance with federal law. Plans that meet the definition of a “grandfathered” plan are not subject to EHB requirements. State specific requirements may vary. Wellfleet Rx will monitor for ACA-related guidance and updates to ensure compliance with all regulations.

January 2024 Updates:
- Addition of Arexvy and Abrysvo for Respiratory Syncytial Virus. Both products available at no copay for anyone over age of 60 years old. Arexvy also available at no copay for pregnant individuals between 32-36 weeks gestational age. If these coverage criteria are not met, the vaccinations are not covered.

Standard EHB Zero Copay Table
All medications, including specified OTC items (e.g., aspirin, contraceptives, folic acid), included on the Wellfleet Rx EHB Zero Copay table are covered at zero copay if the member has a valid prescription; however, some medications are only covered at a zero copay for the population specified (e.g., specified age range). The table below contains the specific drug list contained in the EHB Zero Copay Table.

<table>
<thead>
<tr>
<th>Drug or Vaccine</th>
<th>Edit</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EHB Aspirin Drug List</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aspirin</td>
<td>N/A</td>
<td>Generics only</td>
</tr>
<tr>
<td><strong>EHB Fluoride Drug List</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fluoride</td>
<td>Age 6 months to 6 years</td>
<td>Generics only</td>
</tr>
<tr>
<td><strong>EHB Folic Acid Drug List</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Folic acid</td>
<td>N/A</td>
<td>Generics only</td>
</tr>
<tr>
<td>0.4 mg, 0.8 mg, 1mg</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>EHB Contraceptives Drug List</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Products, documents and materials provided by Wellfleet, including the material contained therein, are proprietary to Wellfleet Group, LLC and protected by applicable copyright or trade secrets laws. Information contained within may not be published, distributed, or reproduced, in part or whole, without express written consent of Wellfleet Group, LLC. Wellfleet is the marketing name used to refer to the insurance and administrative operations of Wellfleet Insurance Company, Wellfleet New York Insurance Company, and Wellfleet Group, LLC. All insurance products are administered or managed by Wellfleet Group, LLC. Product availability is based on regulatory approval and may differ among companies.

©2023 Wellfleet Group, LLC. All rights reserved. Wellfleetrx.com

CSP-SHIP-AUGUST-2023-4
<table>
<thead>
<tr>
<th>Oral and ring hormonal contraceptives</th>
<th>• Step therapy (if applicable)</th>
<th>Generics and single-source brands (SSB)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Transdermal contraceptives</td>
<td>N/A</td>
<td>Generics only (Xulane by Mylan)</td>
</tr>
</tbody>
</table>
| Other contraceptive forms          | • Nexplanon: Limited to 1 per year  
• Depo-Provera: Limited to 1 per 90 days | Covered products include the following: 
• Depo-Provera  
• Liletta  
• Mirena  
• Nexplanon  
• ParaGard  
• Skyla  
• Phexxi |

**EHB Barrier Contraceptives Drug List**

| Barrier contraceptives | Female condoms: 30 per 30 days | Cervical cap  
Diaphragms  
Nonoxynol 9  
Female condoms |

**EHB Breast Cancer Prevention Drug List**

- Raloxifene  
- Tamoxifen  
- Soltamox  
- Anastrazole  
- Exemestane  

- Anastrazole: Age ≥ 35 years; limited to 1 per day  
- Exemestane: Age ≥ 35 years; limited to 1 per day  
- Raloxifene: Limited to 1 per day  

Brands and generics

**EHB Bowel Preparation Drug List**

Products, documents and materials provided by Wellfleet, including the material contained therein, are proprietary to Wellfleet Group, LLC and protected by applicable copyright or trade secrets laws. Information contained within may not be published, distributed, or reproduced, in part or whole, without express written consent of Wellfleet Group, LLC. Wellfleet is the marketing name used to refer to the insurance and administrative operations of Wellfleet Insurance Company, Wellfleet New York Insurance Company, and Wellfleet Group, LLC. All insurance products are administered or managed by Wellfleet Group, LLC. Product availability is based on regulatory approval and may differ among companies.

©2023 Wellfleet Group, LLC. All rights reserved. Wellfleetrx.com
FDA-approved bowel preparations, including but not limited to the following:
- Bisacodyl
- Clenpiq
- PEG 3350 plus electrolytes (e.g., Colyte, Golytely, Moviprep, Nulytely)
- Magnesium citrate
- Magnesium hydroxide
- OsmoPrep
- Plenvu
- Prepopik
- Sodium phosphate
- Suclear
- Suprep
- Sutab

<table>
<thead>
<tr>
<th>EHB Pre-Diabetes Drug List</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metformin immediate-release tablets, extended-release tablets, and solution</td>
</tr>
<tr>
<td>Generic products; for members aged 35 years or older who have been diagnosed with pre-diabetes</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EHB HIV Pre-Exposure Prophylaxis (PrEP) Drug List</th>
</tr>
</thead>
<tbody>
<tr>
<td>Descovy (emtricitabine/tenofovir alafenam)</td>
</tr>
<tr>
<td>Truvada (emtricitabine, FTC/tenofovir disoproxil fumarate, TDF)</td>
</tr>
<tr>
<td>Apretude (cabotegravir) extended-release injectable suspension</td>
</tr>
<tr>
<td>Descovy: Quantity limit of 1 tablet per day</td>
</tr>
<tr>
<td>Generic Truvada: Quantity limit of 1 tablet per day</td>
</tr>
<tr>
<td>Apretude: Quantity limit of 1 injection every 8 weeks</td>
</tr>
<tr>
<td>No concurrent use of HIV medications for the treatment of HIV</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>EHB Statin Drug List</th>
</tr>
</thead>
<tbody>
<tr>
<td>N/A</td>
</tr>
</tbody>
</table>

©2023 Wellfleet Group, LLC. All rights reserved. Wellfleetrx.com

CSP-SHIP-AUGUST-2023-4
### Low-moderate intensity statins
- Altoprev (lovastatin ER) 20-60 mg
- Crestor (rosuvastatin) 5-10 mg
- Ezallor Sprinkle (rosuvastatin) 5-10 mg
- Flolipid (simvastatin suspension) 20mg/5mL, 40mg/5mL
- Lescol (fluvastatin) 20-40 mg, 40 mg twice daily
- Lescol XL (fluvastatin) 80 mg
- Lipitor (atorvastatin) 10-20 mg
- Livalo (pitavastatin calcium) 1-4 mg
- Mevacor (lovastatin) 20-40 mg
- Pravachol (pravastatin) 10-80 mg
- Zocor (simvastatin) 10-40 mg
- Zypitamag (pitavastatin magnesium) 1-4 mg

### EHB Smoking Cessation Drug List
<table>
<thead>
<tr>
<th>Drug</th>
<th>Age</th>
<th>Quantity limit</th>
<th>Availability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bupropion (Zyban)</td>
<td>≥ 18 years</td>
<td></td>
<td>Generic only</td>
</tr>
<tr>
<td>Varenicline (Chantix)</td>
<td>≥ 18 years</td>
<td></td>
<td>Brand and generic</td>
</tr>
<tr>
<td>Nicotine inhaler</td>
<td>≥ 18 years</td>
<td></td>
<td>OTC</td>
</tr>
<tr>
<td>Nicotine spray</td>
<td>≥ 18 years</td>
<td></td>
<td>OTC</td>
</tr>
</tbody>
</table>

*Secondary prevention medications include:
- aspirin/dipyridamole
- clopidogrel
- dipyridamole
- nitroglycerin – oral, sublingual, transdermal, translingual
- prasugrel
- Praluent
- Repatha
- ticagrelor (Brilinta)
- ticlopidine
- vorapaxar (Zontivity)
<table>
<thead>
<tr>
<th>Products</th>
<th>Age Requirements</th>
<th>Quantity Limit</th>
<th>Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nicotine gum or lozenge</td>
<td>Age ≥ 18 years</td>
<td>Quantity limit</td>
<td>OTC</td>
</tr>
<tr>
<td>Nicotine transdermal patches</td>
<td>Age ≥ 18 years</td>
<td>Quantity limit</td>
<td>OTC</td>
</tr>
</tbody>
</table>

**EHB Vaccines – Influenza**

| Influenza vaccines          | 1 dose per 180 days | Flublok, Fluzone High Dose, Fluzone Intradermal, and Fluad will continue to have adult age edits |

**EHB Vaccines – Other**

<table>
<thead>
<tr>
<th>Vaccine Details</th>
<th>Age Requirements</th>
<th>Quantity Limit</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>COVID-19</td>
<td>N/A</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Moderna [mRNA]</td>
<td>N/A</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Pfizer [mRNA] (Comirnaty)</td>
<td>N/A</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Novavax [Ad]</td>
<td>N/A</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Diphtheria, tetanus, pertussis [DTaP] (Infanrix, Daptacel)</td>
<td>N/A</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Diphtheria, tetanus, pertussis [DTaP]/Polio (Quadracel, Kinrix)</td>
<td>N/A</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Diphtheria, tetanus, pertussis [DTaP]/Hepatitis B/Polio (Pediarix)</td>
<td>N/A</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Diphtheria, tetanus, pertussis [DTaP]/ Polio/ Haemophilus influenzae type B/ Hepatitis B (Vaxelis)</td>
<td>N/A</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Diphtheria, tetanus, pertussis [DTaP]/Polio/ Haemophilus influenzae type B (Pentacel)</td>
<td>N/A</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Human papillomavirus (Gardasil, Gardasil 9)</td>
<td>Age 9-45 years</td>
<td>3 doses per 365 days</td>
<td>N/A</td>
</tr>
<tr>
<td>Hepatitis A (Vaqta, Havrix)</td>
<td>2 doses per 365 days</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Hepatitis B (Engerix-B, Recombivax HB, Heplisav-B)</td>
<td>3 doses per 365 days (Engerix-B Adult; Recombivax HB)</td>
<td>2 doses per 365 days (Heplisav-B)</td>
<td>N/A</td>
</tr>
<tr>
<td>Hepatitis B/Hepatitis A combo (TwinRix)</td>
<td>Age ≥18 years</td>
<td>4 doses per 365 days</td>
<td>N/A</td>
</tr>
<tr>
<td>Vaccine</td>
<td>Requirement</td>
<td>Availability</td>
<td></td>
</tr>
<tr>
<td>--------------------------------</td>
<td>----------------------------------------------------------------------------</td>
<td>--------------</td>
<td></td>
</tr>
<tr>
<td><em>Haemophilus influenzae</em> type B (ActHIB, Hiberix, PedvaxHIB)</td>
<td>N/A</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Japanese Encephalitis (Ixiaro)</td>
<td>N/A</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Measles, mumps, rubella (M-M-R II, Priorix)</td>
<td>2 doses per 365 days</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Measles, mumps, rubella, varicella (MMRV) (ProQuad)</td>
<td>N/A</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Meningococcal serogroup B [MenB (Bexsero, Trumenba)]</td>
<td>Age 10-25 years, 2 doses per 365 days (Bexsero), 3 doses per 365 days (Trumenba)</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Meningococcal quadrivalent conjugate [MenACWY (Menactra, Menveo, MenQuadfl)]</td>
<td>Age 11-23 years, unless required upon freshman admission, 1 dose per 365 days</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Pneumococcal polysaccharide (Pneumovax 23)</td>
<td>1 dose per 365 days, Age ≥ 19 years, if immunocompromised</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Pneumococcal conjugate (Prevnar 13, Prevnar 20, Vaxneuvance)</td>
<td>Prevnar 20, Vaxneuvance: Age ≥ 65 years, Age ≥ 19 years, if immunocompromised</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Poliovirus (Ipol)</td>
<td>N/A</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Respiratory syncytial virus (Arexvy, Abryso) – new as of 1/1/24</td>
<td>Arexvy: Age ≥ 60 years, Abryso: Age ≥ 60 years OR in pregnant individuals between 32-36 weeks gestational age</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Rotavirus (Rotarix, Rotateq)</td>
<td>N/A</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Tetanus, diphtheria, pertussis [Tdap (Adacel, Boostrix)]</td>
<td>1 dose per 365 days</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Tetanus, diphtheria [Td (Tenivac, Tdva)]</td>
<td>1 dose per 365 days</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Varicella (Varivax)</td>
<td>2 doses per 365 days</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Zoster vaccine, recombinant (Shingrix)</td>
<td>Age ≥ 50 years, Age ≥ 19 years, if immunocompromised, 2 doses per 365 days</td>
<td>N/A</td>
<td></td>
</tr>
</tbody>
</table>